IL111273A - Carbamoyl esters of 6-dahemethyl glanthamines and pharmacy preparations containing them - Google Patents

Carbamoyl esters of 6-dahemethyl glanthamines and pharmacy preparations containing them

Info

Publication number
IL111273A
IL111273A IL111273A IL11127394A IL111273A IL 111273 A IL111273 A IL 111273A IL 111273 A IL111273 A IL 111273A IL 11127394 A IL11127394 A IL 11127394A IL 111273 A IL111273 A IL 111273A
Authority
IL
Israel
Prior art keywords
compound
hydrogen
demethyl
galanthamine
pharmaceutically acceptable
Prior art date
Application number
IL111273A
Other languages
English (en)
Hebrew (he)
Other versions
IL111273A0 (en
Inventor
Raymond W Kosley Jr
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of IL111273A0 publication Critical patent/IL111273A0/xx
Publication of IL111273A publication Critical patent/IL111273A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL111273A 1993-10-15 1994-10-13 Carbamoyl esters of 6-dahemethyl glanthamines and pharmacy preparations containing them IL111273A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,443 US6323196B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
IL111273A0 IL111273A0 (en) 1994-12-29
IL111273A true IL111273A (en) 1998-04-05

Family

ID=22477457

Family Applications (1)

Application Number Title Priority Date Filing Date
IL111273A IL111273A (en) 1993-10-15 1994-10-13 Carbamoyl esters of 6-dahemethyl glanthamines and pharmacy preparations containing them

Country Status (24)

Country Link
US (1) US6323196B1 (sv)
EP (2) EP1020469A3 (sv)
JP (1) JP2718637B2 (sv)
KR (1) KR100189043B1 (sv)
CN (1) CN1039011C (sv)
AT (1) ATE201687T1 (sv)
AU (1) AU679560B2 (sv)
CA (1) CA2118171C (sv)
CZ (1) CZ283561B6 (sv)
DE (1) DE69427332T2 (sv)
DK (1) DK0648771T3 (sv)
EG (1) EG20747A (sv)
ES (1) ES2158876T3 (sv)
FI (1) FI108724B (sv)
GR (1) GR3036068T3 (sv)
IL (1) IL111273A (sv)
NO (1) NO307463B1 (sv)
NZ (1) NZ264681A (sv)
PL (1) PL177754B1 (sv)
PT (1) PT648771E (sv)
RO (1) RO114132B1 (sv)
RU (1) RU2113438C1 (sv)
TW (1) TW375615B (sv)
ZA (1) ZA948060B (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
JP5558648B2 (ja) 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
PT1140105E (pt) 1998-12-24 2004-03-31 Janssen Pharmaceutica Nv Composicao de galantamina de libertacao controlada
CA2393301A1 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
EP1181294B1 (de) 2000-03-31 2004-03-31 Sanochemia Pharmazeutika Aktiengesellschaft Neue derivate und analoga von galanthamin
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
US20050260613A1 (en) * 2003-10-28 2005-11-24 Genaissance Pharmaceuticals LRPAP1 genetic markers associated with galantamine
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
WO2006004201A1 (ja) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
EP2316437B1 (en) * 2005-05-13 2014-07-30 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
KR100786371B1 (ko) * 2006-12-07 2007-12-17 한국화학연구원 갈란타민의 제조방법
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
MX2012000939A (es) * 2009-07-23 2012-06-08 Shire Llc Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
AU632458B2 (en) * 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
NO307463B1 (no) 2000-04-10
TW375615B (en) 1999-12-01
CN1108658A (zh) 1995-09-20
EP0648771B1 (en) 2001-05-30
FI944822A0 (sv) 1994-10-13
ATE201687T1 (de) 2001-06-15
RU94036761A (ru) 1996-09-10
NO943894L (no) 1995-04-18
FI944822A (sv) 1995-04-16
IL111273A0 (en) 1994-12-29
CZ254794A3 (en) 1995-05-17
AU679560B2 (en) 1997-07-03
DE69427332T2 (de) 2001-10-11
US6323196B1 (en) 2001-11-27
CA2118171C (en) 1999-12-28
GR3036068T3 (en) 2001-09-28
RO114132B1 (ro) 1999-01-29
KR100189043B1 (ko) 1999-06-01
KR950011444A (ko) 1995-05-15
PT648771E (pt) 2001-09-28
FI108724B (sv) 2002-03-15
DE69427332D1 (de) 2001-07-05
RU2113438C1 (ru) 1998-06-20
NO943894D0 (no) 1994-10-14
JP2718637B2 (ja) 1998-02-25
EP1020469A2 (en) 2000-07-19
EG20747A (en) 2000-01-31
ES2158876T3 (es) 2001-09-16
DK0648771T3 (da) 2001-08-27
PL305455A1 (en) 1995-04-18
CA2118171A1 (en) 1995-04-16
PL177754B1 (pl) 2000-01-31
EP1020469A3 (en) 2000-07-26
CZ283561B6 (cs) 1998-05-13
ZA948060B (en) 1995-06-09
JPH07188238A (ja) 1995-07-25
EP0648771A1 (en) 1995-04-19
AU7581294A (en) 1995-05-04
CN1039011C (zh) 1998-07-08
NZ264681A (en) 1997-12-19

Similar Documents

Publication Publication Date Title
CA2118171C (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
FI108723B (sv) Förfarande för framställning av 6-esterderivat av terapeutiskt avändbara 4a,5,9,10,11,12-hexahydro-11-metyl-6H-bensofuro[3a,3,2-ef][2]bensazepin-3,6-diol
CA2118172C (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
FI90240C (sv) Förfarande för framställning av terapeutiskt aktiva 8-aminosubstituerade-7,8-dihydro-6,6-dimetyl-6H-pyrano/2,3-f/benso-2,1,3-oxadiazoler
CA2035397C (en) Hexahydropyrrolo¬2,3-b|indole carbamates, -ureas, -amides and related compounds, a process for their preparation and their use as medicaments
US5091541A (en) Hexahydropyrrolo(2,3-B)indole carbamates, ureas, amides and related compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
FF Patent granted
KB Patent renewed
EXP Patent expired